Center 1 | Center 2 | Combined data | |||||||
---|---|---|---|---|---|---|---|---|---|
Nevirapine (n = 67) (%) | Efavirenz (n = 74) (%) | Effect size (95% CI) | Nevirapine (n = 77) (%) | Efavirenz (n = 66) (%) | Effect size (95% CI) | Nevirapine (n = 144) (%) | Efavirenz (n = 140) (%) | Effect size (95% CI) | |
Composite unfavorable outcome | |||||||||
Unadjusted | 30 (44.8%) | 29 (39.2%) | 5.6% (−10.7,21.9) | 19 (24.7%) | 22 (33.3%) | −8.7% (−23.6,6.2) | 49 (34%) | 51 (36.4%) | −2.4% (−13.5,8.7) |
Adjusted for stage | 44.1% | 39.7% | −7.8% (−33.3,7.7) | 26.2% | 34.8% | 4% (−6.4,14.5) | 35.3% | 36.9% | 4.5% (−5.1,14) |
ART failure | |||||||||
Unadjusted | 20 (29.9%) | 22 (29.7%) | 1.2% (−15,15) | 19 (24.7%) | 20 (30.3%) | −5.6% (−20.7,9.1) | 40 (27.8%) | 43 (30.7%) | −2.9% (−13.5,8.7) |
Adjusted for stage | 29.5% | 30% | −4.3% (−28,19.5) | 27.5% | 33.2% | 2.8% (−7.7,13.3) | 28.7% | 31.3% | 13.2% (−7.8,10.5) |
Death | |||||||||
Unadjusted | 13 (19.4%) | 10 (13.5%) | 5.9% (−6.4,18.2) | 6 (7.8%) | 7 (10.6%) | −2.8% (−12.4,6.7) | 19 (13.2%) | 17 (12.1%) | 1.1% (−6.7,8.8) |
Adjusted for stage | 18.4% | 14.4% | −11.7% (−30.7,7.3) | 8.2% | 11.1% | 0.05% (−6.7,6.8) | 13.6% | 12.4% | −0.2 (−6.9,6.4) |
Successful TB treatment at 48 weeks | |||||||||
Unadjusted | 39 (58.2%) | 39 (52.7%) | 5.5% (−10.9,22) | 63 (81.8%) | 51 (77.3%) | 4.5% (−7.6,18.8) | 102 (71.3%) | 90 (64.3%) | 7% (−3.8,17.9) |
Adjusted for stage | 59.4% | 51.6% | 15.2% (−10.4,40.8) | 84.6% | 79.5% | −4.1% (−12.8,4.7) | 71.5% | 65.6% | −7% (−16.2,2.2) |